Somewhat Favorable News Coverage Somewhat Unlikely to Impact BIOLASE (BIOL) Share Price

News coverage about BIOLASE (NASDAQ:BIOL) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BIOLASE earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the medical technology company an impact score of 43.8972878670746 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of BIOLASE (BIOL) remained flat at $$0.45 during trading on Friday. The stock had a trading volume of 107,194 shares, compared to its average volume of 178,890. The company has a market capitalization of $46.05, a P/E ratio of -1.45 and a beta of 1.93. BIOLASE has a fifty-two week low of $0.28 and a fifty-two week high of $1.57.

In other BIOLASE news, major shareholder Larry N. Feinberg purchased 12,545,615 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The stock was bought at an average cost of $0.43 per share, for a total transaction of $5,394,614.45. The transaction was disclosed in a document filed with the SEC, which is available through this link. 7.10% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/18/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-biolase-biol-share-price.html.

About BIOLASE

BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.

Insider Buying and Selling by Quarter for BIOLASE (NASDAQ:BIOL)

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply